-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, August 31.
On August 30, the official website of NMPA showed that Kelun Pharmaceutical's SGLT-2 inhibitor canagliflozin tablets were approved for marketing, making it the third domestic company
.
In addition, Kelun Pharmaceutical's telbivudine tablets for imitation of category 4 have recently entered the administrative approval stage and are expected to become the first imitation in China
.
Telbivudine is an anti-hepatitis B virus.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 300 million yuan
.
On August 30, the official website of NMPA showed that Kelun Pharmaceutical's SGLT-2 inhibitor canagliflozin tablets were approved for marketing, making it the third domestic company
.
In addition, Kelun Pharmaceutical's telbivudine tablets for imitation of category 4 have recently entered the administrative approval stage and are expected to become the first imitation in China
.
Telbivudine is an anti-hepatitis B virus.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 300 million yuan
.
Telbivudine is an anti-hepatitis B virus drug used in adult patients with chronic hepatitis B who have evidence of viral replication and persistently elevated serum transaminase (ALT or AST) or evidence of active liver tissue lesions
.
.
Telbivudine and entecavir, adefovir dipivoxil, lamivudine, tenofovir and other nucleoside drugs are the main treatment of hepatitis B treatment
.
According to data from Mi Nei.
com, in 2020, the total sales of telbivudine in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies will exceed 300 million yuan.
The manufacturer Novartis monopolizes the market
.
.
According to data from Mi Nei.
com, in 2020, the total sales of telbivudine in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies will exceed 300 million yuan.
The manufacturer Novartis monopolizes the market
.
Affected by the intensive listing of competing products and the inclusion of centralized procurement, the market size of telbivudine has continued to decline in recent years.
In 2020, the terminal sales of public medical institutions in China will decline by 34.
25%, and the terminal sales of physical pharmacies in Chinese cities will increase from 1.
59 in 2015.
100 million yuan fell to 59.
45 million yuan in 2020
.
In 2020, the terminal sales of public medical institutions in China will decline by 34.
25%, and the terminal sales of physical pharmacies in Chinese cities will increase from 1.
59 in 2015.
100 million yuan fell to 59.
45 million yuan in 2020
.
Telbivudine sales in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In the domestic market, only Kelun Pharmaceutical has imitated telbivudine tablets.
At present, the registration status of this product has been changed to "under approval"
.
At the same time, the domestic market of telbivudine tablets is also expected to reverse its decline with the help of generic drugs
.
At present, the registration status of this product has been changed to "under approval"
.
At the same time, the domestic market of telbivudine tablets is also expected to reverse its decline with the help of generic drugs
.
Data source: Mi Neiwang database, NMPA
Medical Network, August 31.
On August 30, the official website of NMPA showed that Kelun Pharmaceutical's SGLT-2 inhibitor canagliflozin tablets were approved for marketing, making it the third domestic company
.
In addition, Kelun Pharmaceutical's telbivudine tablets for imitation of category 4 have recently entered the administrative approval stage and are expected to become the first imitation in China
.
Telbivudine is an anti-hepatitis B virus.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 300 million yuan
.
On August 30, the official website of NMPA showed that Kelun Pharmaceutical's SGLT-2 inhibitor canagliflozin tablets were approved for marketing, making it the third domestic company
.
In addition, Kelun Pharmaceutical's telbivudine tablets for imitation of category 4 have recently entered the administrative approval stage and are expected to become the first imitation in China
.
Telbivudine is an anti-hepatitis B virus.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 300 million yuan
.
Telbivudine is an anti-hepatitis B virus drug used in adult patients with chronic hepatitis B who have evidence of viral replication and persistently elevated serum transaminase (ALT or AST) or evidence of active liver tissue lesions
.
.
Telbivudine and entecavir, adefovir dipivoxil, lamivudine, tenofovir and other nucleoside drugs are the main treatment of hepatitis B treatment
.
According to data from Mi Nei.
com, in 2020, the total sales of telbivudine in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies will exceed 300 million yuan.
The manufacturer Novartis monopolizes the market
.
.
According to data from Mi Nei.
com, in 2020, the total sales of telbivudine in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies will exceed 300 million yuan.
The manufacturer Novartis monopolizes the market
.
Affected by the intensive listing of competing products and the inclusion of centralized procurement, the market size of telbivudine has continued to decline in recent years.
In 2020, the terminal sales of public medical institutions in China will decline by 34.
25%, and the terminal sales of physical pharmacies in Chinese cities will increase from 1.
59 in 2015.
100 million yuan fell to 59.
45 million yuan in 2020
.
In 2020, the terminal sales of public medical institutions in China will decline by 34.
25%, and the terminal sales of physical pharmacies in Chinese cities will increase from 1.
59 in 2015.
100 million yuan fell to 59.
45 million yuan in 2020
.
Telbivudine sales in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In the domestic market, only Kelun Pharmaceutical has imitated telbivudine tablets.
At present, the registration status of this product has been changed to "under approval"
.
At the same time, the domestic market of telbivudine tablets is also expected to reverse its decline with the help of generic drugs
.
At present, the registration status of this product has been changed to "under approval"
.
At the same time, the domestic market of telbivudine tablets is also expected to reverse its decline with the help of generic drugs
.
Data source: Mi Neiwang database, NMPA
Medical Network, August 31.
On August 30, the official website of NMPA showed that Kelun Pharmaceutical's SGLT-2 inhibitor canagliflozin tablets were approved for marketing, making it the third domestic company
.
In addition, Kelun Pharmaceutical's telbivudine tablets for imitation of category 4 have recently entered the administrative approval stage and are expected to become the first imitation in China
.
Telbivudine is an anti-hepatitis B virus.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 300 million yuan
.
On August 30, the official website of NMPA showed that Kelun Pharmaceutical's SGLT-2 inhibitor canagliflozin tablets were approved for marketing, making it the third domestic company
.
In addition, Kelun Pharmaceutical's telbivudine tablets for imitation of category 4 have recently entered the administrative approval stage and are expected to become the first imitation in China
.
Telbivudine is an anti-hepatitis B virus.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 300 million yuan
.
Telbivudine is an anti-hepatitis B virus drug used in adult patients with chronic hepatitis B who have evidence of viral replication and persistently elevated serum transaminase (ALT or AST) or evidence of active liver tissue lesions
.
.
Telbivudine and entecavir, adefovir dipivoxil, lamivudine, tenofovir and other nucleoside drugs are the main treatment of hepatitis B treatment
.
According to data from Mi Nei.
com, in 2020, the total sales of telbivudine in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies will exceed 300 million yuan.
The manufacturer Novartis monopolizes the market
.
Hospital hospital hospital pharmacy pharmacy pharmacy.
According to data from Mi Nei.
com, in 2020, the total sales of telbivudine in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and Chinese urban physical pharmacies will exceed 300 million yuan.
The manufacturer Novartis monopolizes the market
.
Affected by the intensive listing of competing products and the inclusion of centralized procurement, the market size of telbivudine has continued to decline in recent years.
In 2020, the terminal sales of public medical institutions in China will decline by 34.
25%, and the terminal sales of physical pharmacies in Chinese cities will increase from 1.
59 in 2015.
100 million yuan fell to 59.
45 million yuan in 2020
.
In 2020, the terminal sales of public medical institutions in China will decline by 34.
25%, and the terminal sales of physical pharmacies in Chinese cities will increase from 1.
59 in 2015.
100 million yuan fell to 59.
45 million yuan in 2020
.
Telbivudine sales in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
In the domestic market, only Kelun Pharmaceutical has imitated telbivudine tablets.
At present, the registration status of this product has been changed to "under approval"
.
At the same time, the domestic market of telbivudine tablets is also expected to reverse its decline with the help of generic drugs
.
At present, the registration status of this product has been changed to "under approval"
.
At the same time, the domestic market of telbivudine tablets is also expected to reverse its decline with the help of generic drugs
.
Data source: Mi Neiwang database, NMPA
